[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Bardou
M
M
Unité de pharmacologie clinique, LPPCE faculté de médecine de Dijon, 21079 Dijon.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000367:Age Factors; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004381:Duodenal Ulcer / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D011899:Ranitidine / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy; D013454:Sulfoxides / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D064750:Rabeprazole; D011899:Ranitidine; D000077402:Pantoprazole; D009853:Omeprazole